November 24, 2013

OLYSIO™ (simeprevir): Quick Facts -- What You Need to Know

November 24, 2013
By Patricia Emory

OLYSIO™ (simeprevir) was approved in the United States November 22, 2013 by the FDA for the treatment of hepatitis C patients in conjunction with pegylated interferon and ribavirin in adult patients (treatment-naive and treatment-experienced) with genotype 1 including those with compensated cirrhosis.

OLYSIO™ (simeprevir) is a “2nd generation”  NS3/4A protease inhibitor which acts by blocking the protease enzyme that enables the virus to replicate.

Dosing and Duration of treatment

Dosing: Fixed dose of 150mg once a day

Duration of Treatment:

Treatment-naïve and prior-relapsers: 12 weeks of Simeprevir in combination with 24 weeks of pegylated interferon and ribavirin

Partial and null-responders: 12 weeks of Simeprevir in combination with 48 weeks of pegylated interferon and ribavirin

Adverse Effects

The most common adverse effects of Simeprevir are rash and sensitivity to sunlight (most common in the first 4 weeks of treatment) as well as those associated with pegylated interferon and ribavirin.

Q80K polymorphism

Q80K polymorphism is found in 56.7% of genotype 1a patients in the US. The Q80K polymorphism  greatly reduces treatment response. It is suggested that all patients being considered for treatment using Simeprevir be screened for the Q80K polymorphism.

Financial Assistance

According to the OLYSIO™ website:

“Information on financial assistance through OLYSIO Support will be available soon. In the meantime, please call1-800-JANSSEN (1-800-526-7736) for information.”

Further Information

OLYSIO™ (simeprevir) website 

OLYSIO™ (simeprevir) Receives FDA Approval for Combination Treatment of Chronic Hepatitis C – Janssen Press Release

FDA approves new treatment for hepatitis C virus – FDA Press Release

FDA Antiviral Drugs Advisory Committee Meeting Briefing Document

No comments:

Post a Comment